ASML's Washington Problem Overshadows a Quiet $1.1 Billion Vote of Confidence

ASML stock dips 7.3% weekly on proposed MATCH Act targeting China chip-equipment sales; fundamentals remain strong with raised guidance.

The most consequential news for ASML shareholders right now isn't tucked into an earnings release or a fund manager's regulatory filing — it's a piece of draft legislation making its way through Washington. Reports that the proposed MATCH Act would empower the US to pressure the Dutch government into banning "virtually all" chip-equipment sales to China surfaced on Thursday, and for a company whose growth story has long been intertwined with Chinese demand, the implications are hard to overstate.

The stock closed Friday at €1,507.80, up 0.4% on the day but still down 7.3% for the week. That slide has accelerated a pullback that began well before the political headlines: shares have now given back 4.5% since the early-August peak that followed ASML's blockbuster second-quarter results.

A Political Mechanism, Not a Market One

What makes the MATCH Act threat distinct from the export restrictions ASML has navigated for years is its sheer scope. Previous curbs were surgical, targeting high-end EUV systems. A blanket prohibition on nearly all chip-making tools destined for China would strike at a market that has historically been a major revenue pillar — even if its relative weight in ASML's order book has been deliberately shrinking.

The diplomatic mechanics matter here. Washington cannot regulate ASML directly; it must work through The Hague. That creates room for negotiation, but also a prolonged period of uncertainty that markets tend to price in quickly and reluctantly.

At €1,511.20 in recent trading, the stock sits 2.6% below its 50-day moving average while remaining 21% above the 200-day line. The RSI reads 48.1, suggesting neither oversold nor overbought conditions. For chart watchers, this looks less like a trend reversal than a consolidation phase following an extraordinary run — the shares have roughly two-and-a-half times since last September's low.

One Manager's Exit, Read Carefully

Against that backdrop, a newly disclosed Form 13F filing shows US asset manager AlTi Global slashed its ASML position by 76.3% during the second quarter of 2026. It's the kind of headline that invites alarm, but context matters: institutional rebalancing of this sort often reflects fund-specific allocation logic — profit-taking after a massive run-up, for instance — rather than a fundamental verdict on the company.

The distinction is worth keeping in mind because the operational picture remains robust. ASML delivered €9.3 billion in second-quarter revenue at a 54% gross margin, guided third-quarter sales to €11–12 billion, and raised its full-year outlook to €43–45 billion. Intel Foundry has moved to high-volume production of its "Panther Lake" processors using ASML's High-NA EUV systems — tangible proof that the industry's most expensive machines can deliver at scale.

The buyback program, meanwhile, continues on schedule: roughly €1.1 billion of repurchases were executed in the second quarter under the 2026–2028 framework. The interim dividend of €1.88 per share was paid out about three weeks ago, and the stock has since recovered 3.2% from that ex-dividend dip.

Analysts Hold Their Ground — For Now

Barclays and DBS both reaffirmed buy ratings on August 20 and August 17, respectively. That analysts have held their ground despite the geopolitical overhang is notable, though it may say more about the lag time in adjusting models than about durable conviction. Once the MATCH Act takes more concrete form, those ratings could shift quickly.

The October Test

The next major catalyst arrives October 14, when ASML reports third-quarter results. Consensus expects earnings per share of €10.38 on revenue of €11.31 billion, bracketed by management's own guidance of €11.0–12.0 billion in net sales and a 55–57% gross margin. The company has also signaled plans to ship around 65 low-NA EUV systems this year, a target that will be closely scrutinized as evidence that its growth ambitions remain on track.

For now, the fundamental story is intact — strong orders, technological leadership, and a management team willing to back its own stock with real money. But the variable that will likely determine whether the past twelve months' rally resumes or stalls is not operational. It's political. And it's playing out in Washington, not Veldhoven.